Aspen Labs Mexico – Carlos Abelleyra Cordero, CEO Spanish LATAM
Aspen Labs wants Latin America to be the third pillar of success for the company, and is doing it in a different way. The CEO for Spanish Latin America discusses…
Ranked as the ninth largest generic company in the world, South African-based Aspen is a supplier of branded and generic pharmaceuticals in more than 150 countries across the world and of consumer and nutritional products in selected territories. The Group currently has 50 business units , 26 manufacturing facilities at 18 sites on 6 continents and approximately 8200 employees. In Latin America Aspen supplies a range of quality affordable products through its affiliate companies in Mexico, Argentina, Brazil and Venezuela as well as across the rest of Latin America in countries such as Chile, Colombia, Ecuador and the Carricam territories. Aspen sees Latin America as one of its key strategic regions with significant growth potential within the Group, and continues to seek opportunities to establish a greater presence in other Latin American countries.
Contact Details
Aspen Labs, S.A. De C.V.
Av. Insurgentes Sur 1685
Col. Guadalupe Inn, Del. Alvaro Obregón
C.P. 01020 México D.F.
Tel: +52 (55) 9126 0860
Website: aspenlabs.com.mx
Aspen Labs wants Latin America to be the third pillar of success for the company, and is doing it in a different way. The CEO for Spanish Latin America discusses…
The Aspen Group identified Latin America as a “large developing market where it can leverage its substantial intellectual property portfolio and manufacturing infrastructure”. What was the original strategy behind getting…
Below is a selection of top recent news from Mexican pharma and healthcare, including the healthcare reforms president Andres Manuel Lopez Obrador is prioritising, latest news on the INSABI program,…
Between 2015 and 2017 PharmaBoardroom met with pharma country managers in Mexico who spoke about the challenges and opportunities present in the Mexican market. Since then, these five stakeholders have…
The United States Trade Representative Office has been engaging with a number of countries, including Mexico, to address concerns related to IP protection and enforcement and market access barriers for…
What traits, competencies and drivers do you need to be a successful pharma country manager in today’s dynamic Mexican pharma market? Jose Guerrero and Male Mejido from the Mexico office…
Cristobal Thompson of the AMIIF examines the steps forward that Mexican pharma has made in countering corruption, the areas in which urgent improvement is still needed, and outlines the three…
Cristobal Thompson is the executive director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). In this article, he introduces us to an exciting new youth program set up to improve…
Cristobal Thompson is the Executive Director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). The AMIIF represents more than 60 global companies with the aim of contributing to improving health…
David Peña Castillo, president and founder of the Mexican Federation of Rare Diseases (FEMEXER), addresses the problem of patients deserting therapies. In Mexico, approximately 15 percent of patients treated…
Cristobal Thompson is the executive director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). The AMIIF represents more than 60 global companies with the aim of contributing to improving health…
Cristobal Thompson is the Executive Director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). The AMIIF represents more than 60 global companies with the aim of contributing to improving health…
Cristobal Thompson is the Executive Director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). The AMIIF represents more than 60 global companies with the aim of contributing to improving…
David Peña Castillo is the President and founder of The Mexican Federation of Rare Diseases (FEMEXER). Here he discusses what makes a patients association. When we find a way to…
See our Cookie Privacy Policy Here
